Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $10
Lipella Pharmaceuticals Gains Buy Rating From Jason McCarthy Following Positive Phase 2a Results for LP-310
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Announces Target Price $10
Lipella Pharmaceuticals Receives Buy Rating Amidst Promising FDA Approval and Strategic Financial Moves
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed: Lipella Pharmaceuticals' Innovative Drug Delivery and Clinical Advancements Propel Optimism
Buy Rating Affirmed for Lipella Pharmaceuticals on LP-310's Phase 2a Enrollment and Strategic Advantages
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Lipella Pharmaceuticals (LIPO.US) was first covered by Maxim Group and given a buy rating, with a target price of $2.00.
Lipella Pharmaceuticals Analyst Ratings